|RAS017-C01||Pre-coated with SARS-CoV-2 Spike RBD Microplate||1 plate|
|RAS017-C02||Anti-SARS-CoV-2 Antibody (Control, IgG4)||10 μg|
|RAS017-C03||HRP-Mouse anti-Human IgG4||10 μg|
|RAS017-C04||10 x Washing Buffer||50 mL|
|RAS017-C05||Dilution Buffer||50 mL|
|RAS017-C06||Substrate Solution||12 mL|
|RAS017-C07||Stop Solution||7 mL|
After reconstitution, the stock solution should be kept at -70°C.
It is recommended not to freeze thaw more than 3 times.
Your experiment will include 4 simple steps:
a) Add your sample to the plate, take the Anti-SARS-CoV-2 antibody as Control sample. The samples and Control sample are diluted by Dilution Buffer.
b) Add diluted Secondary antibody HRP-Mouse-Anti-Human IgG4 to the plate. The Secondary antibody is diluted by Dilution Buffer.
c) Wash the plate and add TMB or other colorimetric HRP substrate.
d) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Detection of Anti-SARS-CoV-2 Antibody, Human IgG4 titer by Indirect-ELISA Assay.
Immobilized SARS-CoV-2 Spike RBD at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG4 in 1:50 human serum. Detection was performed using HRP-Conjugated Anti-human IgG4 antibody with sensitivity of 10 ng/mL (QC tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.